Drug
Brentuximab Vedotin
Brentuximab Vedotin: highest development phase Phase 3, developed by Seagen, Takeda, United Therapeutics. 16 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Seagen, Takeda, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Brentuximab vedotin NCT04404283 | Phase 3 | Diffuse Large B-cell Lymphoma |
| Brentuximab Vedotin NCT03264131 | Phase 2 | Lymphoma |
| brentuximab vedotin NCT01716806 | Phase 2 | Hodgkin Disease |
| brentuximab vedotin NCT03947255 | Phase 2 | Hodgkin Lymphoma |
| brentuximab vedotin NCT04569032 | Phase 2 | Peripheral T-cell Lymphoma |
| Brentuximab vedotin NCT01396070 | Phase 2 | Non-Hodgkin Lymphoma (NHL) |
| Brentuximab Vedotin NCT04795869 | Phase 2 | Recurrent Angioimmunoblastic T-Cell Lymphoma |
| Brentuximab Vedotin NCT04334174 | Phase 2 | T Cell Lymphoma |
| brentuximab vedotin NCT01421667 | Phase 2 | Lymphoma, B-Cell |
| brentuximab vedotin NCT00848926 | Phase 2 | Disease, Hodgkin |
| Brentuximab vedotin NCT02979522 | Phase 1/2 | Hodgkin Disease |
| Brentuximab Vedotin NCT01596218 | Phase 1 | Graft vs. Host Disease |
| brentuximab vedotin NCT01026415 | Phase 1 | Carcinomas |
| Brentuximab vedotin NCT01578967 | Not Applicable | Hodgkin Lymphoma, Adult |
| Brentuximab vedotin NCT01841021 | Not Applicable | Peripheral T-Cell Lymphoma |
| Brentuximab vedotin (SGN-35) NCT01868451 | Not Applicable | Hodgkin Lymphoma |
Latest
No recent events.
Follow Brentuximab Vedotin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.